Diabetic retinopathy affects nearly all young patients with type 1 diabetes

Article

One in three young Danish patients with type 1 diabetes mellitus progressed to proliferative diabetic retinopathy, and two in three had 2-step progression despite their young age, according to study results recently published in the November 2013 issue of Acta Diabetologica. In addition, these researchers from Denmark found that after 30-years? duration of diabetes, the presence of diabetic retinopathy was almost universal.

One in three young Danish patients with type 1 diabetes mellitus progressed to proliferative diabetic retinopathy, and two in three had 2-step progression despite their young age, according to study results recently published in Acta Diabetologica. In addition, these researchers from Denmark found that after 30-years' duration of diabetes, the presence of diabetic retinopathy was almost universal.

From 1987 to 1989, these researchers identified a paediatric cohort of children that included approximately 75% of all children in Denmark with type 1 diabetes

In 1995, mean patient age was 21.0 years, and mean duration of diabetes was 13.5 years. The 16-year incidence of proliferative retinopathy was 31.0%, 2-step progression was 64.4% and 2-step regression of diabetic retinopathy was 0.0%. The incidence of diabetic retinopathy was 95.1%.

Upon multivariate logistic regression modelling, progression to proliferative diabetic retinopathy was significantly associated with HbA1c levels in 1995 (OR: 2.61 per 1% increase, 95% CI: 1.85-3.68) and diastolic BP of 1995 (OR: 1.79 per 10 mmHg increase, 95% CI: 1.04-3.07). Two-step progression of diabetic retinopathy was associated with male gender (OR: 2.37 versus female, 95% CI: 1.07-5.27), 1995 HbA1c (OR: 3.02per 1% increase, 95% CI: 2.04-4.48), and 1995 vibration perception threshold (OR: 1.19 per 1 volt increase, 95% CI: 1.02-1.40).

To access these data, click here.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.